Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.
Hosted on MSN16d
Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment
Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
The New York Times17d
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. By Brendan Borrell When Stephane Castel first ...
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.
Morningstar17d
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk to Discover Novel Targets for Metabolic Disease
Collaboration leverages Variant Bio's innovative VB-Inference Platform and expertise partnering with global populations Commercial terms include an upfront payment and additional near-term R&D ...
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.